- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02248857
Promoting the Universal Medication Schedule Via Mobile and EHR Technologies
Promoting the Universal Medication Schedule Via Mobile and EHR Technologies: A Physician-randomized Control Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Research has shown the UMS (1) improves patients' understanding of how much to take of a medicine and when, and (2) reduces the number of times per day patients would take a multi-drug regimen. In this study, UMS tools will be exported into a second electronic health record platform to demonstrate ease of dissemination. Also, as patients may require assistance outside of clinic visits to adapt their prescription regimen to the UMS, this study will test the potential benefit of daily short message service (SMS) text reminders via cell phone.
We will conduct a three-arm, provider-randomized controlled trial among English and Spanish-speaking adults taking three or more prescription drugs to evaluate the effectiveness of the UMS strategy, with and without SMS text reminders, to improve patient understanding, consolidation, and adherence compared to usual care.We will conduct a three-arm, provider-randomized trial at two community health centers in Chicago, IL to evaluate the UMS and UMS+SMS text reminder strategies compared to usual care. English and Spanish-speaking patients who are prescribed three or more medications will be recruited and assessed by phone at baseline, three months, and six months.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- diagnosis of type II diabetes
- age 30 or older
- taking 3 or more prescription medications for chronic conditions
- English or Spanish speaking
Exclusion Criteria:
- self-reported severe, uncorrectable vision
- hearing impairment
- cognitive impairment
- not responsible for administering his/her own medications
- not able to receive text messages on their cell phone
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: Usual Care
Employ the current standard of care.
No intervention.
|
|
Experimental: UMS strategy
Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
|
Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
|
Experimental: UMS strategy + SMS texting reminders
In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
|
Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prescription Understanding
Time Frame: 6 months after baseline
|
Predictive probabilities of prescription understanding will be calculated based on patients' ability to correctly dose their prescription medications using unadjusted Generalized Estimating Equation models, specifying the binomial family and logit link, with medication as the unit of analysis.
Correct dosing per medication will be scored as yes or no, reflecting having demonstrated all of the following: proper dose (# of pills), spacing (hours between doses), frequency (# of times per day), and total pills per day.
Results are presented as predicted probabilities with 95% Confidence Intervals.
|
6 months after baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Medication Knowledge
Time Frame: 6 months after baseline
|
Predictive probabilities of medication knowledge will be calculated based on patients' ability to identify each medication's purpose and side effects, risks, warnings, and benefits using unadjusted Generalized Estimating Equation models, specifying the binomial family and logit link, with medication as the unit of analysis.
Patients will be asked through a structured questionnaire about each of the above via structured, open-ended items.
Each medication will be scored as correct/incorrect if the participant knew the purpose and could name at least 1 side effect, risk, or warning of the medication.
Results are presented as predicted probabilities with 95% Confidence Intervals.
|
6 months after baseline
|
Medication Adherence: Pill Count
Time Frame: 6 months after baseline
|
Predictive probabilities of medication adherence will be calculated based on telephone pill counts using unadjusted Generalized Estimating Equation models, specifying the binomial family and logit link, with medication as the unit of analysis.
Pills taken/pills prescribed will be calculated for each medication and scored as adherent for that medication if that score is between 80% and 120%.
Results are presented as predicted probabilities with 95% Confidence Intervals.
|
6 months after baseline
|
Medication Adherence: PMAQ
Time Frame: 6 months after baseline
|
Predictive probabilities of medication adherence will be calculated based on a 4-item validated Patient Medication Adherence Questionnaire (PMAQ) using unadjusted Generalized Estimating Equation models, specifying the binomial family and logit link, with medication as the unit of analysis.
The PMAQ assesses adherence behaviors by asking patients to self-report missed/wrong doses in past 4 days, scoring each medication as adherent for that medication if no missed doses were reported.
Results are presented as predicted probabilities with 95% Confidence Intervals.
|
6 months after baseline
|
Medication Adherence: Pharmacy Records
Time Frame: 6 months after baseline
|
Predictive probabilities of primary medication adherence will be calculated based on the proportion of days covered (PDC) with medication obtained from pharmacy records using unadjusted Generalized Estimating Equation models, specifying the binomial family and logit link, with medication as the unit of analysis.
PDC is calculated by summing the number of days' supply obtained by a patient during a given time period and dividing by the number of days for which the patient was prescribed the medication.
Each medication is scored as adherent if the patient was covered for that medication more than 80% of the time.
Results are presented as predicted probabilities with 95% Confidence Intervals.
|
6 months after baseline
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in Blood Pressure
Time Frame: 6 months before baseline to 1 year after baseline
|
An exploratory analysis will be conducted to investigate the impact of receiving the UMS in either intervention arm on biologic outcomes for these prevalent conditions.
Systolic blood pressure will be obtained from patients' electronic health records.
Differences will be measured between the last clinical measurement prior to baseline assessment and the last measured value during the study period (closest to 6 month assessment).
|
6 months before baseline to 1 year after baseline
|
Changes in Hemoglobin A1c (hbA1c)
Time Frame: 6 months before baseline to 1 year after baseline
|
An exploratory analysis will be conducted to investigate the impact of receiving the UMS in either intervention arm on biologic outcomes for these prevalent conditions.
Hemoglobin A1c (hbA1c) will be obtained from patients' electronic health records.
Differences will be measured between the last clinical measurement prior to baseline assessment and the last measured value during the study period (closest to 6 month assessment).
|
6 months before baseline to 1 year after baseline
|
Changes in Low-density Lipoprotein Cholesterol (LDL)
Time Frame: 6 months before baseline to 1 year after baseline
|
An exploratory analysis will be conducted to investigate the impact of receiving the UMS in either intervention arm on biologic outcomes for these prevalent conditions.
Low-density lipoprotein cholesterol (LDL) will be obtained from patients' electronic health records.
Differences will be measured between the last clinical measurement prior to baseline assessment and the last measured value during the study period (closest to 6 month assessment).
|
6 months before baseline to 1 year after baseline
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael Wolf, PhD, MPH, Northwestern University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- STU00097744
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
Antonio Di MauroCompletedType-2 DiabetesItaly
-
DiaMedica Therapeutics IncCompletedDiabetes Type 2Netherlands
-
RenJi HospitalUnknownType 2 Diabetes.China
-
University of Erlangen-Nürnberg Medical SchoolCompletedType 2-diabetesGermany
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Not yet recruitingType 2 Diabetes Mellitus
-
Nanjing First Hospital, Nanjing Medical UniversityRecruitingType 2 Diabetes MellitusChina
-
Xiangya Hospital of Central South UniversityRecruitingType 2 Diabetes MellitusChina
-
University of Alabama at BirminghamCompletedType 2 Diabetes MellitusUnited States
-
Imperial College LondonAstraZeneca; Huma; North West London Collaboration of CCGs (NWL CCGs); Imperial...CompletedType 2 Diabetes MellitusUnited Kingdom
-
Universiti Sains MalaysiaCompleted
Clinical Trials on UMS Strategy
-
Northwestern UniversityIcahn School of Medicine at Mount Sinai; Emory University; Northwestern Memorial...CompletedDiabetes Mellitus, Type 2 | Medication AdherenceUnited States
-
Hospices Civils de LyonNot yet recruiting
-
China National Center for Cardiovascular DiseasesUnknown
-
Centre Hospitalier Universitaire de NīmesCompletedCentral Venous CatheterizationFrance
-
Assistance Publique - Hôpitaux de ParisMinistry of Health, FranceCompleted
-
Yale UniversityNational Institute of Allergy and Infectious Diseases (NIAID); National Heart...CompletedTuberculosis | Tuberculosis, PulmonaryUganda
-
Alliance for International Medical ActionHarvard School of Public Health (HSPH); University of Bordeaux, INSERM, Bordeaux...CompletedAcute Malnutrition in Infancy (Disorder)Niger
-
Medical University of South CarolinaCompleted
-
University Hospital, AngersRecruitingPhysical Activity | AgedFrance
-
University Hospital, AngersUnknownAcute Respiratory Distress SyndromeFrance